{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T06:33:03Z","timestamp":1775370783586,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Mental Health\/National Institute of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.ejphar.2011.09.162","type":"journal-article","created":{"date-parts":[[2011,9,25]],"date-time":"2011-09-25T21:13:16Z","timestamp":1316985196000},"page":"39-44","source":"Crossref","is-referenced-by-count":16,"title":["The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents"],"prefix":"10.1016","volume":"671","author":[{"given":"Aloke K.","family":"Dutta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaskar","family":"Gopishetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjib","family":"Gogoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solav","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"Reith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2011.09.162_bb0005","first-page":"395","article-title":"Bupropion: a review of its mechanism of antidepressant activity","volume":"56","author":"Ascher","year":"1995","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0010","series-title":"Goodman and Gilman's The Pharmacological Basis of the Therapeutica","author":"Baldessarini","year":"1996"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0190","series-title":"Goodman & Gilman's The Pharmnacological Basis of Therapeutics","first-page":"443","author":"Baldessarini","year":"2006"},{"issue":"Suppl. 15","key":"10.1016\/j.ejphar.2011.09.162_bb0015","first-page":"42","article-title":"SSRI safety in overdose","volume":"59","author":"Barbey","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1021\/jm00002a020","article-title":"Cocaine and 3 beta-(4\u2032-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter","volume":"38","author":"Carroll","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","article-title":"Comparison of pramipexole, fluoxetine, and placebo in patients with major depression","volume":"11","author":"Corrigan","year":"2000","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0014-2999(00)00566-5","article-title":"The role of dopamine in the mechanism of action of antidepressant drugs","volume":"405","author":"D'Aquila","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archpsyc.64.3.327","article-title":"The role of dopamine in the pathophysiology of depression","volume":"64","author":"Dunlop","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2008.05.008","article-title":"D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action","volume":"589","author":"Dutta","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0197-0186(93)90144-T","article-title":"Cocaine-sensitive and -insensitive dopamine uptake in prefrontal cortex, nucleus accumbens and striatum","volume":"23","author":"Elsworth","year":"1993","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0050","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1177\/0269881198012003041","article-title":"Selective serotonin reuptake inhibitors in the treatment of affective disorders\u2014III. Tolerability, safety and pharmacoeconomics","volume":"12","author":"Goldstein","year":"1998","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0165-1781(96)02879-X","article-title":"Plasma dopamine and norepinephrine correlations with psychomotor retardation, anxiety, and depression in non-psychotic depressed patients: a pilot study","volume":"64","author":"Hamner","year":"1996","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","article-title":"Pharmacokinetics of selective serotonin reuptake inhibitors","volume":"85","author":"Hiemke","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0065","series-title":"Psychopharmacology The third Generation of Progress","first-page":"505","article-title":"Role of dopamine mechanisms in affective disorder","author":"Jimerson","year":"1987"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0070","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/cmdc.200900085","article-title":"Synthesis and biological characterization of (3R,4R)-4-(2-(benzhydryloxy)ethyl)-1-((R)-2-hydroxy-2-phenylethyl)-piperid in-3-ol and its stereoisomers for activity toward monoamine transporters","volume":"4","author":"Kharkar","year":"2009","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0075","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0006-3223(02)01383-5","article-title":"Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study","volume":"52","author":"Klimek","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0080","first-page":"50","article-title":"Triple reuptake inhibitors: next-generation antidepressants","author":"Liang","year":"2008","journal-title":"Prim. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0085","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/jpet.108.143610","article-title":"Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)","volume":"327","author":"Liang","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nurt.2008.10.039","article-title":"Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs","volume":"6","author":"Millan","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0095","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/070674370004500509","article-title":"Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians","volume":"45","author":"Mischoulon","year":"2000","journal-title":"Can. J. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2011.09.162_bb0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/(SICI)1520-6394(1998)8:1+<5::AID-DA2>3.0.CO;2-I","article-title":"The serotonin transporter and depression","volume":"8","author":"Owens","year":"1998","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0105","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/266730a0","article-title":"Depression: a new animal model sensitive to antidepressant treatments","volume":"266","author":"Porsolt","year":"1977","journal-title":"Nature"},{"issue":"Suppl. 13","key":"10.1016\/j.ejphar.2011.09.162_bb0110","first-page":"5","article-title":"Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance","volume":"64","author":"Richelson","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0115","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/archpsyc.1985.01790350055010","article-title":"Plasma norepinephrine level in affective disorders. Relationship to melancholia","volume":"42","author":"Roy","year":"1985","journal-title":"Archives of general psychiatry"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0120","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-3565(25)39088-9","article-title":"Preclinical evaluation of McN-5707 as a potential antidepressant","volume":"242","author":"Shank","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejphar.2006.10.004","article-title":"Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050","volume":"555","author":"Shaw","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(03)01310-4","article-title":"Antidepressant-like actions of DOV 21,947: a \u201ctriple\u201d reuptake inhibitor","volume":"461","author":"Skolnick","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0140","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1016\/j.lfs.2003.06.007","article-title":"\u201cBroad spectrum\u201d antidepressants: is more better for the treatment of depression?","volume":"73","author":"Skolnick","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0145","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2174\/0929867024606795","article-title":"Serotonin reuptake inhibition: an update on current research strategies","volume":"9","author":"Spinks","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/10401230009147102","article-title":"Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review","volume":"12","author":"Sporn","year":"2000","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0155","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0160","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1192\/bjp.178.3.234","article-title":"Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors","volume":"178","author":"Thase","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0165","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00179933","article-title":"Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor","volume":"93","author":"Thomas","year":"1987","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2011.09.162_bb0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-4615-1857-0_11","article-title":"Development of antidepressant drugs. Fluoxetine (Prozac) and other selective serotonin uptake inhibitors","volume":"363","author":"Wong","year":"1995","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0175","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1021\/jm0601699","volume":"49","author":"Zhang","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0180","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1021\/jm049021k","article-title":"Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner","volume":"48","author":"Zhang","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2011.09.162_bb0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejphar.2004.10.028","article-title":"Interaction between a hydroxypiperidine analogue of 4-(2-benzhydryloxy-ethyl)-1-(4-fluorobenzyl)piperidine and Aspartate 68 in the human dopamine transporter","volume":"506","author":"Zhen","year":"2004","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911011459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911011459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T01:01:49Z","timestamp":1741741309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299911011459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":38,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0014299911011459"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.09.162","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}